Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

CPET-based HIIT for MAFLD

High-intensity interval training (HIIT), as an individualized exercise training mode based on cardiopulmonary exercise testing (CPET), is characterized by high-intensity training sessions interspersed with short rest periods. The findings from recent trials suggest that in the management of metabolic dysfunction-associated fatty liver disease (MAFLD), compared with traditional aerobic exercise modes such as moderate-intensity continuous training, HIIT may achieve similar or even better effects in reducing liver fat content, increasing peak oxygen uptake, improving insulin resistance, and lowering blood pressure, despite requiring less time commitment and lower energy expenditure. However, there is currently no consensus regarding the formulation of HIIT exercise protocols. Based on the lower limits of the current mainstream HIIT intensity, sets, and interval time parameters, this study aims to assess the effectiveness, safety, and feasibility of the current exercise prescription in improving MAFLD.

Participants needed: 54
Trial details
Age: 35-65Biological sex: AllType: InterventionalSponsor: Tang YidaUpdated: Sep 17, 2025Locations: 5
Eligibility criteria

Overweight or Obesity: ≥ 24kg/m2,or waist circumference ≥ 90 cm in men and > 85... [+4]

Contraindications for Cardiopulmonary Exercise Testing [+7]

Status: Not yet recruiting

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).

Participants needed: 5,200
Trial details
Phase: Phase 4Age: 40-75Biological sex: AllType: InterventionalSponsor: Tang YidaUpdated: Nov 3, 2021Locations: 1
Eligibility criteria

Patients diagnosed with metabolic syndrome aged 40-75 years old. [+1]

Previously diagnosed diabetes. [+14]